Malignant melanoma of eyelid

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Phase I (First in Human): 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; NIVOLUMAB
    2024-513062-19-00 1 country 2022 n=8
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
New trials by year
2022
1
← All indication landscapes